Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.

Clinical transplantation - 1 Dec 2015

Punzalan Carmi Santos, Barry Curtis, Zacharias Isabel, Rodrigues Julie, Mehta Savant, Bozorgzadeh Adel, Barnard Graham F

Abstract excerpt

BACKGROUND: Patients with recurrent hepatitis C (HCV) infection post-liver transplant can be difficult to treat safely and effectively. A prior (COSMOS) study in patients with non-transplant HCV, using sofosbuvir plus simeprevir, had high efficacy and tolerability in treating patients with HCV genotype 1, even prior non-responders to interferon therapy and those with cirrhosis. Our aim was to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C

Share to Liver Transplantation

Share to Recurrence

Share to Simeprevir

Share to Sofosbuvir

Source

Identifiers

PMID: 26358816
DOI: 10.1111/ctr.12634

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.PMID 26358816Read ↗

Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Semantic proximity Read ↗

Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.Semantic proximity Read ↗

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.Semantic proximity Read ↗

Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.Semantic proximity Read ↗

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.Semantic proximity Read ↗

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.Semantic proximity Read ↗

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.Semantic proximity Read ↗

Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.Semantic proximity Read ↗

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Semantic proximity Read ↗

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.